Rapid Micro Biosystems, Inc.
NASDAQ:RPIDMedical - Devices
+$0.03 today
- Market cap
- $50.31M
- Beta
- 1.46
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$1.10
Volume 0.17M
Average 0.18M
RPID EBITDA Margin
EBITDA as a percentage of revenue.
Rapid Micro Biosystems, Inc.NASDAQ: RPID
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -161.5%
EBITDA Margin was -161.5% in Q1 FY2026, down 17.0 pp from a year earlier. On a trailing-twelve-month basis it was -131.2%, up 8.9 pp year over year. Over 3 fiscal years it widened by 214.5 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 3 analysts of -96.4% for the fiscal year ending Dec 2026, up from -127.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -161.5%-65.0 pp QoQ
- Last fiscal yearDec 2025
- -127.3%+27.8 pp YoY
- LTMMar 2026
- -131.2%+8.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -17.0 pp | +24.1 pp | +41.1 pp |
| 1 year | +27.8 pp | +30.9 pp | +3.1 pp |
| 3 years | +214.5 pp | +106.8 pp | -107.6 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -127.3%
- Year-over-year change
- +27.8pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -127.3% | +27.8pp |
| FY2024 | 2024-12-31 | -155.1% | +64.0pp |
| FY2023 | 2023-12-31 | -219.1% | +122.6pp |
| FY2022 | 2022-12-31 | -341.7% | -43.6pp |
| FY2021 | 2021-12-31 | -298.1% | — |
EBITDA Margin vs competitors
How RPID compares with its peers on the latest reported figures
- RPID's LTM Mar 2026 EBITDA Margin of -131.2% is the 5th highest of the 7 companies compared; the peer median is -46.3%.
- Its year-over-year change of +8.9 pp is the 5th highest of 7, against a peer median of +21.1 pp.
- Over three fiscal years its change of +214.5 pp compares with a peer median of +30.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 58.8% | +150.4 pp | -4.3 pp | |
| LTM Mar 2026 | -4.4% | +24.0 pp | +40.8 pp | |
| LTM Mar 2026 | -40.4% | -29.4 pp | +75.4 pp | |
| LTM Mar 2026 | -52.1% | +18.1 pp | +20.4 pp | |
| LTM Mar 2026 | -131.2% | +8.9 pp | +214.5 pp | |
| LTM Mar 2026 | -859.3% | +600.4 pp | +13170.1 pp | |
| LTM Mar 2026 | -54764.9% | -26826.7 pp | -22063.2 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding RPID) | -46.3% | +21.1 pp | +30.6 pp | |
Competitors are the stored peer set for RPID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 23.23M | 17.13M | 22.52M | 28.05M | 33.59M |
| Cost of Revenue | 30.97M | 25.67M | 28M | 28.16M | 25.98M |
| Gross Profit | (7.74M) | (8.54M) | (5.49M) | (109K) | 7.61M |
| Gross Margin | -33.3% | -49.8% | -24.4% | -0.4% | 22.7% |
| Research & Development | 9.78M | 12.87M | 12.82M | 14.6M | 13.6M |
| Selling, General & Admin | 29.71M | 41.81M | 38.26M | 35.21M | 34.84M |
| Operating Expenses | 39.49M | 54.68M | 51.08M | 49.81M | 55M |
| Depreciation & Amortization | 1.53M | 2.84M | 3.11M | 3.36M | 3.25M |
| EBITDA | (69.25M) | (58.55M) | (49.33M) | (43.51M) | (42.74M) |
| EBITDA Margin | -298.1% | -341.7% | -219.1% | -155.1% | -127.3% |
| Operating Income | (47.23M) | (63.22M) | (56.56M) | (49.92M) | (47.39M) |
| Operating Margin | -203.3% | -369.0% | -251.2% | -178.0% | -141.1% |
| Interest Income | 0 | 1.78M | 4.21M | 3.16M | 1.51M |
| Interest Expense | 2.65M | 0 | 0 | 0 | 1.09M |
| Other Income / Expenses | (26.2M) | 1.84M | 4.13M | 3.05M | 309K |
| Income Before Tax | (73.43M) | (61.38M) | (52.44M) | (46.87M) | (47.08M) |
| Pre-Tax Margin | -316.1% | -358.3% | -232.9% | -167.1% | -140.2% |
| Income Tax Expense | 91K | (576K) | 31K | 22K | 40K |
| Net Income | (73.52M) | (60.81M) | (52.47M) | (46.89M) | (47.12M) |
| Net Margin | -316.5% | -354.9% | -233.0% | -167.2% | -140.3% |
| EPS (Basic) | (1.88) | (1.43) | (1.22) | (1.08) | (1.05) |
| EPS (Diluted) | (1.88) | (1.43) | (1.22) | (1.08) | (1.05) |
| Weighted Avg Shares | 41.47M | 42.45M | 43.02M | 43.58M | 44.68M |
| Weighted Avg Shares (Diluted) | 41.47M | 42.45M | 43.02M | 43.58M | 44.68M |
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
Intrinsic Alpha fair value
Locked
Current Price
$1.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.